Multidrug-resistant Tuberculosis
Genient Technologies is your trusted partner in the fight against MDR-TB, working tirelessly to
improve healthcare outcomes, ensure patient well-being, and contribute to the global mission of
eradicating this challenging disease. Together, we can make a difference in the lives of those
affected by MDR-TB and shape a healthier future for all. Explore our innovative solutions and join us
in advancing healthcare and scientific discovery.
One of the pressing healthcare challenges we are dedicated to addressing is
Multi-Drug-Resistant Tuberculosis (MDR-TB). MDR-TB is a form of tuberculosis (TB) that has developed
resistance to at least two of the most potent first-line anti-TB drugs, isoniazid and rifampicin. This
resistance complicates treatment and poses a significant global health concern.
Key Aspects of MDR-TB
Drug Resistance
MDR-TB arises when TB bacteria become resistant to isoniazid and rifampicin, rendering standard TB treatments ineffective.
Complex Treatment
Treating MDR-TB involves prolonged courses of second-line drugs, often with more side effects and lower success rates.
Higher Mortality
MDR-TB is associated with a higher mortality rate due to treatment challenges and
limited drug options.
Our Role in Combating MDR-TB
Genient Technologies is at the forefront of tackling MDR-TB through innovative solutions:
Diagnostic Tools
We offer cutting-edge diagnostic tools, including drug susceptibility testing (DST) and rapid molecular tests like GeneXpert, to accurately identify MDR-TB cases.
Research Support
We support researchers in their quest to better understand MDR-TB, develop new treatments, and advance our collective knowledge.
Global Impact
We are committed to global health and work collaboratively to combat MDR-TB's spread and impact on vulnerable populations.